Advances in immunotherapy for pancreatic cancer: 2013.
نویسندگان
چکیده
Pancreatic cancer is one of the more difficult malignancies to treat, and there is a great need for less toxic, effective regimens. Immunotherapy has shown potential in the treatment of pancreatic cancer, and at ASCO 2013 there were several progressive advances in its clinical application. Abstracts #3067, #3049, #3007, #4040, #LBA4004, and #3090 will be discussed. New developments in the field of immunotherapy are promising novel treatments for pancreatic neoplasms with tolerable side effect profiles.
منابع مشابه
Recent Advancements in Pancreatic Cancer Immunotherapy
The overarching goal of this review is to highlight the current progress of immunotherapy in pancreatic cancer. Despite all the efforts, pancreatic cancer remains a disease that is refractory to almost all therapies and immunotherapy for pancreatic cancer remains in its infancy. In this review, we summarize promising advances and major hurdles in developing immunotherapeutic strategies for panc...
متن کاملCurrent Immunotherapeutic Approaches in Pancreatic Cancer
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pa...
متن کاملWhat Is Recent in Pancreatic Cancer Immunotherapy?
Pancreatic cancer (PC) represents an unresolved therapeutic challenge, due to the poor prognosis and the reduced response to currently available treatments. Pancreatic cancer is the most lethal type of digestive cancers, with a median survival of 4-6 months. Only a small proportion of PC patients is curative by surgical resection, whilst standard chemotherapy for patients in advanced disease ge...
متن کاملImmunotherapy for Pancreatic Cancer
Patients with pancreatic cancer have an especially poor prognosis, with a 5-year survival rate of <1% and a median survival of 4-6 months (Jemal, Siegel et al., 2010). The management of patients with pancreatic cancer depends on the extent of the disease at diagnosis. However, approximately 80% of patients present with advanced-stage disease that precludes surgical resection (pancreaticoduodene...
متن کاملA self antigen reopens the games in pancreatic cancer
We have recently demonstrated that the administration of a plasmid coding for α-enolase can elicit robust immune responses in genetically engineered mice that spontaneously develop pancreatic cancer, resulting in a significant improvement of their survival. This approach provides a springboard for the elaboration of new forms of immunotherapy for pancreatic cancer.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- JOP : Journal of the pancreas
دوره 14 4 شماره
صفحات -
تاریخ انتشار 2013